Skip to main content
SpringerLink
Log in

Pathogenesis and Management of Adiposity and Insulin Resistance in PCOS: Prevention and Treatment of the Metabolic Disease Components

  • Chapter
  • First Online:
Pediatric Obesity

Part of the book series: Contemporary Endocrinology ((COE))

  • 1718 Accesses

Abstract

PCOS is the commonest endocrine disorder of women; it affects 5–10% of the female population and typically presents during adolescence. It is a heterogeneous syndrome, but the classic features are anovulation (irregular menstrual cycles) and symptoms of androgen excess such as hirsutism, acne, and alopecia. The most consistent biochemical abnormality is hyperandrogenaemia, as most commonly defined by higher than normal serum concentrations of testosterone (or androstenedione) and/or an elevated-free androgen index (see below).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333(13):853–61.

    Article  PubMed  CAS  Google Scholar 

  2. Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, editors. Polycystic ovary syndrome. Oxford: Blackwell Scientific Publications. 1992. pp. 377–84.

    Google Scholar 

  3. Rotterdam1. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. Jan 2004;19(1):41–7.

    Article  Google Scholar 

  4. Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab. Mar 2006;91(3):786–9.

    Article  PubMed  CAS  Google Scholar 

  5. Welt CK, Gudmundsson JA, Arason G, et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab. Dec 2006;91(12):4842–8.

    Article  PubMed  CAS  Google Scholar 

  6. Dewailly D, Catteau-Jonard S, Reyss AC, Leroy M, Pigny P. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. J Clin Endocrinol Metab. Oct 2006;91(10):3922–7.

    Article  PubMed  CAS  Google Scholar 

  7. Barber TM, Wass JA, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol. 2007;66(4):513–7.

    CAS  Google Scholar 

  8. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. Nov 2006;91(11):4237–45.

    Article  PubMed  CAS  Google Scholar 

  9. Franks S. Polycystic ovary syndrome in adolescents. Int J Obes (Lond). Jul 2008;32(7):1035–41.

    Article  CAS  Google Scholar 

  10. Eisner JR, Dumesic DA, Kemnitz JW, Abbott DH. Timing of prenatal androgen excess determines differential impairment in insulin secretion and action in adult female rhesus monkeys. J Clin Endocrinol Metab. Mar 2000;85(3): 1206–10.

    Article  PubMed  CAS  Google Scholar 

  11. Eisner JR, Barnett MA, Dumesic DA, Abbott DH. Ovarian hyperandrogenism in adult female rhesus monkeys exposed to prenatal androgen excess. Fertil Steril. Jan 2002;77(1):167–72.

    Article  PubMed  Google Scholar 

  12. Padmanabhan V, Manikkam M, Recabarren S, Foster D. Prenatal testosterone excess programs reproductive and metabolic dysfunction in the female. Mol Cell Endocrinol. 26 Feb 2006;246(1–2):165–74.

    Article  PubMed  CAS  Google Scholar 

  13. Abbott DH, Zhou R, Bird IM, Dumesic DA, Conley AJ. Fetal programming of adrenal androgen excess: lessons from a nonhuman primate model of polycystic ovary syndrome. Endocr Dev. 2008;13:145–58.

    Article  PubMed  CAS  Google Scholar 

  14. Manneras L, Cajander S, Holmang A, et al. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology. Aug 2007;148(8):3781–91.

    Article  PubMed  Google Scholar 

  15. Demissie M, Lazic M, Foecking EM, Aird F, Dunaif A, Levine JE. Transient prenatal androgen exposure produces metabolic syndrome in adult female rats. Am J Physiol Endocrinol Metab. Aug 2008;295(2):E262–8.

    Article  PubMed  CAS  Google Scholar 

  16. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome – a hypothesis. J Endocrinol. Jul 2002;174(1):1–5.

    Article  PubMed  CAS  Google Scholar 

  17. Pastor CL, Griffin-Korf ML, Aloi JA, Evans WS, Marshall JC. Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab. Feb 1998;83(2):582–90.

    Article  PubMed  CAS  Google Scholar 

  18. Eagleson CA, Gingrich MB, Pastor CL, et al. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab. Nov 2000;85(11):4047–52.

    Article  PubMed  CAS  Google Scholar 

  19. McClamrock HD, Adashi EY. Gestational hyperandrogenism. Fertil Steril. Feb 1992;57(2):257–74.

    PubMed  CAS  Google Scholar 

  20. Ibanez L, Jaramillo A, Enriquez G, et al. Polycystic ovaries after precocious pubarche: relation to prenatal growth. Hum Reprod. Feb 2007;22(2):395–400.

    Article  PubMed  CAS  Google Scholar 

  21. Urbanek M. The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab. Feb 2007;3(2):103–11.

    Article  PubMed  CAS  Google Scholar 

  22. Franks S, Gharani N, Waterworth D, et al. The genetic basis of polycystic ovary syndrome. Hum Reprod. Dec 1997;12(12):2641–8.

    Article  PubMed  CAS  Google Scholar 

  23. Legro RS, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA. 8 Dec 1998;95(25):14956–60.

    Article  PubMed  CAS  Google Scholar 

  24. Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome (PCOS) in a Dutch twin-family study. J Clin Endocrinol Metab. 11 Oct 2006;91:2100–4.

    Article  PubMed  CAS  Google Scholar 

  25. Stewart DR, Dombroski BA, Urbanek M, et al. Fine mapping of genetic susceptibility to polycystic ovary syndrome on chromosome 19p13.2 and tests for regulatory activity. J Clin Endocrinol Metab. Oct 2006;91(10):4112–7.

    Article  PubMed  CAS  Google Scholar 

  26. Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 11 May 2007;316(5826):889–94.

    Article  PubMed  CAS  Google Scholar 

  27. Barber TM, Bennett AJ, Groves CJ, et al. Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome. Diabetologia. Jul 2008;51(7):1153–8.

    Article  PubMed  CAS  Google Scholar 

  28. Urbanek M, Woodroffe A, Ewens KG, et al. Candidate gene region for polycystic ovary syndrome (PCOS) on chromosome 19p13.2. J Clin Endocrinol Metab. Dec 2005;90(12):6623–9.

    Google Scholar 

  29. Matzuk MM. Revelations of ovarian follicle biology from gene knockout mice [In Process Citation]. Mol Cell Endocrinol. 2000;163(1–2):61–6.

    Article  PubMed  CAS  Google Scholar 

  30. Zeggini E, Weedon MN, Lindgren CM, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science. 1 Jun 2007;316(5829):1336–41.

    Article  PubMed  CAS  Google Scholar 

  31. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. Dec 1997;18(6):774–800.

    Article  PubMed  CAS  Google Scholar 

  32. Robinson S, Kiddy D, Gelding SV, et al. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol (Oxf). 1993;39(3):351–5.

    Article  CAS  Google Scholar 

  33. Dahlgren E, Johansson S, Lindstedt G, et al. Women with polycystic ovary syndrome wedge resected in 1956–1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril. Mar 1992;57(3):505–13.

    PubMed  CAS  Google Scholar 

  34. Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb). 2000;3(2):101–5.

    Article  Google Scholar 

  35. Solomon CG, Hu FB, Dunaif A, et al. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. Jama. 21 Nov 2001;286(19):2421–6.

    Article  PubMed  CAS  Google Scholar 

  36. Robinson S, Henderson AD, Gelding SV, et al. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf). Mar 1996;44(3):277–84.

    Article  CAS  Google Scholar 

  37. Robinson S, Chan SP, Spacey S, Anyaoku V, Johnston DG, Franks S. Postprandial thermogenesis is reduced in polycystic ovary syndrome and is associated with increased insulin resistance. Clin Endocrinol (Oxf). Jun 1992;36(6):537–43.

    Article  CAS  Google Scholar 

  38. Franks S, Gilling-Smith C, Watson H, Willis D. Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am. Jun 1999;28(2):361–78.

    Article  PubMed  CAS  Google Scholar 

  39. Pasquali R, Antenucci D, Casimirri F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab. Jan 1989;68(1):173–9.

    Article  PubMed  CAS  Google Scholar 

  40. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 24 Mar 2005;352(12):1223–36.

    Article  PubMed  CAS  Google Scholar 

  41. Pasquali R, Gambineri A. Insulin-sensitizing agents in polycystic ovary syndrome. Eur J Endocrinol. Jun 2006;154(6):763–75.

    Article  PubMed  CAS  Google Scholar 

  42. Venkatesan AM, Dunaif A, Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Prog Horm Res. 2001;56:295–308.

    Article  PubMed  CAS  Google Scholar 

  43. Corbould A, Kim YB, Youngren JF, et al. Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab. May 2005;288(5):E1047–54.

    Article  PubMed  CAS  Google Scholar 

  44. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest. Aug 1995;96(2):801–10.

    Article  PubMed  CAS  Google Scholar 

  45. Cohen P. Protein kinases–the major drug targets of the twenty-first century? Nat Rev Drug Discov. Apr 2002;1(4): 309–15.

    Article  PubMed  CAS  Google Scholar 

  46. Rosenbaum D, Haber RS, Dunaif A. Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. Am J Physiol. Feb 1993;264(2 Pt 1):E197–202.

    PubMed  CAS  Google Scholar 

  47. Gaster M, Staehr P, Beck-Nielsen H, Schroder HD, Handberg A. GLUT4 is reduced in slow muscle fibers of type 2 diabetic patients: is insulin resistance in type 2 diabetes a slow, type 1 fiber disease? Diabetes. Jun 2001;50(6):1324–9.

    Article  PubMed  CAS  Google Scholar 

  48. Rice S, Christoforidis N, Gadd C, et al. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum Reprod. Feb 2005;20(2):373–81.

    Article  PubMed  CAS  Google Scholar 

  49. Roberts R, Stark J, Iatropoulou A, Becker DL, Franks S, Hardy K. Energy substrate metabolism of mouse cumulus-oocyte complexes: response to follicle-stimulating hormone is mediated by the phosphatidylinositol 3-kinase pathway and is associated with oocyte maturation. Biol Reprod. Jul 2004;71(1):199–209.

    Article  PubMed  CAS  Google Scholar 

  50. Barber TM, Golding SJ, Alvey C, et al. Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome. J Clin Endocrinol Metab. Mar 2008;93(3):999–1004.

    Article  PubMed  CAS  Google Scholar 

  51. Kiddy DS, Sharp PS, White DM, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf). Feb 1990;32(2):213–20.

    Article  CAS  Google Scholar 

  52. Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf). Aug 2006;65(2):137–45.

    Article  CAS  Google Scholar 

  53. Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab. Sept 1988;67(3):460–4.

    Article  PubMed  CAS  Google Scholar 

  54. Singh A, Hamilton-Fairley D, Koistinen R, et al. Effect of insulin-like growth factor-type I (IGF-I) and insulin on the secretion of sex hormone binding globulin and IGF-I binding protein (IBP-I) by human hepatoma cells. J Endocrinol. Feb 1990;124(2):R1–R3.

    Article  PubMed  CAS  Google Scholar 

  55. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism. Jul 2003;52(7):908–15.

    Article  PubMed  CAS  Google Scholar 

  56. Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol. Jul 2005;106(1):131–7.

    Article  PubMed  Google Scholar 

  57. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. Apr 2005;90(4):1929–35.

    Article  PubMed  CAS  Google Scholar 

  58. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. Jan 2006;91(1):48–53.

    Article  PubMed  CAS  Google Scholar 

  59. Rossi B, Sukalich S, Droz J, et al. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. J Clin Endocrinol Metab. Dec 2008;93(12):4780–6.

    Article  PubMed  CAS  Google Scholar 

  60. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). Jan 1992;36(1):105–11.

    Article  CAS  Google Scholar 

  61. Summerbell CD, Ashton V, Campbell KJ, Edmunds L, Kelly S, Waters E. Interventions for treating obesity in children. Cochrane Database Syst Rev. 2003;3:CD001872.

    PubMed  Google Scholar 

  62. Guttmann-Bauman I. Approach to adolescent polycystic ovary syndrome (PCOS) in the pediatric endocrine community in the USA. J Pediatr Endocrinol Metab. May 2005;18(5):499–506.

    Article  PubMed  Google Scholar 

  63. Koulouri O, Conway GS. A systematic review of commonly used medical treatments for hirsutism in women. Clin Endocrinol (Oxf). May 2008;68(5):800–5.

    Article  CAS  Google Scholar 

  64. Ganie MA, Khurana ML, Eunice M, et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab. Jun 2004;89(6):2756–62.

    Article  PubMed  CAS  Google Scholar 

  65. Ibanez L, Potau N, Marcos MV, de Zegher F. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab. Sept 2000;85(9): 3251–5.

    Article  PubMed  CAS  Google Scholar 

  66. Ibanez L, de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum Reprod Update. May–Jun 2006;12(3):243–52.

    Article  PubMed  CAS  Google Scholar 

  67. Legro RS. Long-term, low-dose flutamide does not cause hepatotoxicity in hyperandrogenic women. Nat Clin Pract Endocrinol Metab. Apr 2006;2(4):188–9.

    Article  PubMed  Google Scholar 

  68. Allen HF, Mazzoni C, Heptulla RA, et al. Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab. Aug 2005;18(8):761–8.

    Article  PubMed  CAS  Google Scholar 

  69. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick D. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab. 2008;93:4299–306.

    Article  PubMed  CAS  Google Scholar 

  70. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab. Apr 2002;87(4):1555–9.

    Article  PubMed  CAS  Google Scholar 

  71. Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 8 Feb 2007;356(6):551–66.

    Article  PubMed  CAS  Google Scholar 

  72. Nissen SE. Perspective: effect of rosiglitazone on cardiovascular outcomes. Curr Cardiol Rep. Sept 2007;9(5):343–4.

    Article  PubMed  Google Scholar 

  73. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. Apr 2007;92(4):1305–10.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Imperial College London, Institute of Reproductive and Developmental Biology, Hammersmith Hospital, London, W2 0NN, UK

    Stephen Franks & Jalini Joharatnam

Authors
  1. Stephen Franks
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jalini Joharatnam
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pediatric Endocrinology, and Diabetes, Duke University, DUMC 3080, Durham, 27710, North Carolina, USA

    Michael Freemark

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Franks, S., Joharatnam, J. (2010). Pathogenesis and Management of Adiposity and Insulin Resistance in PCOS: Prevention and Treatment of the Metabolic Disease Components. In: Freemark, M. (eds) Pediatric Obesity. Contemporary Endocrinology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-60327-874-4_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-874-4_24

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-60327-873-7

  • Online ISBN: 978-1-60327-874-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation